QuidelOrtho Corporation $QDEL Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. trimmed its holdings in shares of QuidelOrtho Corporation (NASDAQ:QDEL) by 0.8% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 7,572,075 shares of the company’s stock after selling 64,118 shares during the period. Vanguard Group Inc. owned 0.11% of QuidelOrtho worth $216,258,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of QDEL. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in QuidelOrtho by 7.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,404 shares of the company’s stock worth $583,000 after acquiring an additional 1,366 shares during the period. Phocas Financial Corp. grew its holdings in QuidelOrtho by 45.7% during the fourth quarter. Phocas Financial Corp. now owns 170,018 shares of the company’s stock worth $4,856,000 after acquiring an additional 53,353 shares during the period. State of Alaska Department of Revenue grew its holdings in QuidelOrtho by 1.1% during the fourth quarter. State of Alaska Department of Revenue now owns 38,333 shares of the company’s stock worth $1,093,000 after acquiring an additional 424 shares during the period. Moody National Bank Trust Division grew its holdings in QuidelOrtho by 1.0% during the fourth quarter. Moody National Bank Trust Division now owns 51,512 shares of the company’s stock worth $1,471,000 after acquiring an additional 526 shares during the period. Finally, SG Americas Securities LLC boosted its position in shares of QuidelOrtho by 16.7% during the 4th quarter. SG Americas Securities LLC now owns 23,710 shares of the company’s stock worth $677,000 after purchasing an additional 3,391 shares in the last quarter. 99.00% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at QuidelOrtho

In other news, Director Matthew Strobeck bought 10,000 shares of QuidelOrtho stock in a transaction on Friday, February 13th. The shares were bought at an average cost of $23.96 per share, for a total transaction of $239,600.00. Following the acquisition, the director owned 27,775 shares in the company, valued at approximately $665,489. This trade represents a 56.26% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Joseph M. Busky purchased 3,370 shares of QuidelOrtho stock in a transaction on Friday, February 13th. The shares were acquired at an average cost of $23.66 per share, for a total transaction of $79,734.20. Following the purchase, the chief financial officer owned 10,290 shares in the company, valued at approximately $243,461.40. This trade represents a 48.70% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have bought 23,910 shares of company stock worth $567,973. Corporate insiders own 0.79% of the company’s stock.

Analyst Ratings Changes

QDEL has been the topic of several research analyst reports. Wall Street Zen lowered shares of QuidelOrtho from a “buy” rating to a “hold” rating in a research report on Sunday, April 12th. UBS Group restated a “neutral” rating and set a $12.00 target price on shares of QuidelOrtho in a research report on Thursday. Jefferies Financial Group lowered shares of QuidelOrtho from a “buy” rating to a “hold” rating and decreased their target price for the stock from $35.00 to $12.50 in a research report on Thursday. Citigroup decreased their target price on shares of QuidelOrtho from $30.00 to $13.00 and set a “neutral” rating on the stock in a research report on Wednesday. Finally, Zacks Research lowered shares of QuidelOrtho from a “hold” rating to a “strong sell” rating in a research report on Tuesday, February 17th. Three equities research analysts have rated the stock with a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, QuidelOrtho presently has a consensus rating of “Reduce” and an average price target of $14.88.

QuidelOrtho Price Performance

NASDAQ:QDEL opened at $10.80 on Friday. The firm has a market cap of $736.46 million, a price-to-earnings ratio of -0.61 and a beta of 0.75. The company has a current ratio of 1.43, a quick ratio of 0.90 and a debt-to-equity ratio of 1.33. The company’s 50-day moving average is $16.15 and its two-hundred day moving average is $23.57. QuidelOrtho Corporation has a 12-month low of $10.21 and a 12-month high of $38.99.

QuidelOrtho (NASDAQ:QDEL) last released its earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). The firm had revenue of $619.80 million during the quarter, compared to analysts’ expectations of $665.23 million. QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. QuidelOrtho’s revenue for the quarter was down 10.5% on a year-over-year basis. During the same quarter last year, the company posted $0.74 earnings per share. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. Research analysts expect that QuidelOrtho Corporation will post 1.9 EPS for the current year.

QuidelOrtho Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.